
This article provides an overview of solutions to address key challenges facing vaccine developers or CDMOs wishing to build their own commercial-scale mRNA production facilities.
Peter Cramer is a subject matter expert in Process Architecture at Jacobs.
This article provides an overview of solutions to address key challenges facing vaccine developers or CDMOs wishing to build their own commercial-scale mRNA production facilities.
Published: August 2nd 2022 | Updated: